In a patient with metastatic ovarian cancer who is being treated for an active deep‑vein thrombosis (DVT), what are the safest pharmacologic options for appetite stimulation?

Safest Appetite Stimulation Options in Ovarian Cancer with Active DVT

In a patient with metastatic ovarian cancer being treated for active DVT, corticosteroids are the safest pharmacologic option for appetite stimulation, given that megestrol acetate and medroxyprogesterone acetate carry significant thromboembolic risk that is absolutely contraindicated in your patient's context.

Primary Recommendation: Corticosteroids

Corticosteroids are proven appetite stimulants with efficacy comparable to progestins but without the thrombotic risk 1, 2. They improve appetite to a similar degree as megestrol acetate but are the only viable option when thromboembolism is a concern 1.

Practical Implementation:

• Use for short-term appetite stimulation in patients with life expectancy of weeks to a few months 1
• Efficacy declines with long-term use, and toxicities accumulate (hyperglycemia, myopathy, immunosuppression, psychiatric effects) 1
• Optimal dosing and scheduling remain undefined, but evidence supports their use 2

Why NOT Progestins in This Patient

Megestrol Acetate - CONTRAINDICATED

• Causes thromboembolic events as a known toxicity 1
• While it improves appetite and body weight (minimum effective dose 160 mg daily) 2, the weight gain is primarily adipose tissue rather than skeletal muscle 1
• The thrombotic risk makes this absolutely inappropriate for a patient with active DVT

Medroxyprogesterone Acetate (MPA) - CONTRAINDICATED

• Also carries thromboembolic risk similar to megestrol acetate 1
• Improves appetite but effect on weight gain is less consistent 2
• Minimum dose shown effective is 200 mg daily 2

Other Agents with Insufficient Evidence

Olanzapine

The 2020 ASCO guideline explicitly does not recommend olanzapine outside clinical trials due to paucity of data, despite promising preliminary evidence 1. While some data suggest appetite improvement, the evidence base is too limited for routine use.

Agents Lacking Benefit

• Cyproheptadine: May have appetite-stimulating effects but adverse effects reported; insufficient evidence 2
• Dronabinol, metoclopramide: No demonstrated appetite-stimulating effects 2
• Hydrazine sulfate: Definitively NOT an appetite stimulant 2
• Thalidomide: Insufficient evidence to support use 1

Clinical Algorithm for Your Patient

1. First-line: Corticosteroids

   • Use as primary appetite stimulant given active DVT
   • Monitor for hyperglycemia, myopathy, and other steroid-related toxicities
   • Plan for short-term use (weeks to months)

2. Address underlying nutrition impact symptoms

   • Evaluate and treat depression, dysgeusia, pain, drowsiness, nausea, constipation 1
   • These symptoms frequently contribute to poor intake and must be managed concurrently

3. Combine with nutritional support

   • Appetite stimulants should be used in combination with or after failure of dietetic and oral nutritional management 2

Critical Caveat

The thrombotic risk of progestins is absolute in your patient with active DVT. While megestrol acetate and MPA are standard options in cancer cachexia 1, 2, 3, the presence of active thrombosis being treated with anticoagulation makes these agents dangerous. The edema and thromboembolic events associated with megestrol acetate 1 would directly worsen your patient's thrombotic burden despite anticoagulation.